Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Acalabrutinib Study With Best Supportive Care in Participants Hospitalized With COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04497948
Recruitment Status : Terminated (

Data from the CALAVI Phase II trials for Acalabrutinib in patients hospitalized with COVID-19 did not meet their primary efficacy endpoints.

Based on this higher management made the decision to prematurely terminate the D822FC00005 PK study.

)
First Posted : August 4, 2020
Last Update Posted : December 2, 2020
Sponsor:
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
Acerta Pharma BV

Brief Summary:
Study D822FC00005 will investigate the Phamacokinetics, Safety and tolerability of Acalabrutinib suspension when delivered via a nasogastric tube and co-administered with a Proton Pump Inhibitor, in the treatment of COVID-19.

Condition or disease Intervention/treatment Phase
COVID-19 Drug: Acalabrutinib Phase 1

Detailed Description:
This study is to support the ongoing clinical development of acalabrutinib (CALQUENCE®) in hospitalized COVID-19 patients. Because many COVID-19 patients may be unable to swallow capsules due to respiratory failure (eg, they may require endotracheal intubation for ventilator support and Naso Gastric tube placement), it is important to have a clinically acceptable method to administer acalabrutinib (capsules) via NG tube. Furthermore, many hospitalized patients are placed on high doses of proton pump inhibitors (PPIs) (also commonly known as antacid medication). This study is designed to determine the Pharmaco Kinetics (effect of body/ bodily systems on the drug), safety and tolerability of acalabrutinib suspension, when coadministered with a PPI, in participants with confirmed SARS-CoV-2 infection requiring hospitalization due to respiratory failure, attributable to COVID-19 pneumonia and who have an Nasogastric (NG) tube in place.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Single group multi dose study. Participants to receive Acalabrutinib + PPI and Best Supportive Care.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Multiple-dose Study of Acalabrutinib, Co Administered With a Proton-pump Inhibitor, in Participants Hospitalized With COVID-19
Actual Study Start Date : September 21, 2020
Actual Primary Completion Date : November 18, 2020
Actual Study Completion Date : November 18, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Single Arm
Single Arm
Drug: Acalabrutinib
Acalabrutinib (CALQUENCE®) is a covalent BTK inhibitor
Other Name: CALQUENCE®




Primary Outcome Measures :
  1. Acalabrutinib and ACP-5862 plasma PK parameter: AUC12h [ Time Frame: Pre-dose and 0.5, 1, 2, 4, 6, and 12 hours post-dose ]
    To assess the AUC12h (area under plasma concentration-time curve from time zero to 12 hours) of the acalabrutinib NG suspension when coadministered with the PPI in participants with COVID-19

  2. Acalabrutinib and ACP-5862 plasma PK parameter: AUClast [ Time Frame: Pre-dose and 0.5, 1, 2, 4, 6, and 12 hours post-dose ]
    To assess the AUClast (area under the plasma concentration-time curve from time zero to time of last quantifiable concentration) of the acalabrutinib NG suspension when coadministered with the PPI in participants with COVID-19

  3. Acalabrutinib and ACP-5862 plasma PK parameter: Cmax [ Time Frame: Pre-dose and 0.5, 1, 2, 4, 6, and 12 hours post-dose ]
    To assess the Cmax (maximum observed plasma concentration) of the acalabrutinib NG suspension when coadministered with the PPI in participants with COVID-19

  4. Type, frequency, severity, and relationship to study intervention of any treatment-emergent AEs or abnormalities of laboratory tests, SAEs, or AEs leading to discontinuation of study intervention [ Time Frame: From screening to 28 days (+/- 3days) after last dose of acalabrutinib ]
    To Assess Safety and tolerability of acalabrutinib suspension in participants with COVID-19 when administered in the presence of PPIs and BSC


Secondary Outcome Measures :
  1. Proportion of participants alive and free of respiratory failure at Days 14 and 28 [ Time Frame: Days 14 and 28 ]
    To evaluate the preliminary efficacy of adding acalabrutinib suspension to BSC for treatment of participants with COVID-19

  2. Percent change from baseline in CRP at Days 3, 5, 7, 14, 28 [ Time Frame: Baseline and Days 3, 5, 7, 14, 28 ]
    To evaluate the preliminary efficacy of adding acalabrutinib suspension to BSC for treatment of participants with COVID-19

  3. Time to improvement- clinical improvement of ≥ 2 points(from first dose date)on a 9-point category ordinal scale Or live discharge from the hospital Or considered fit for discharge(a score of 0,1,or2 on the ordinal scale)whichever comes first,by Day 28 [ Time Frame: Up to Day 28 ]
    To evaluate the preliminary efficacy of adding acalabrutinib suspension to BSC for treatment of participants with COVID-19



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Participant or legally authorized representative must be able to understand the purpose and risks of the study and provide written informed consent and authorization to use protected health information (in accordance with national and local patient privacy regulations).
  2. Participants who are hospitalized with coronavirus (SARS-CoV-2) infection, confirmed by PCR test or other commercial or public health assay in any specimen, as documented by either of the following:

    1. PCR positive in sample collected < 72 hours prior to first dose, OR
    2. PCR positive in sample collected ≥ 72 hours prior to first dose (but no more than 14 days prior to first dose), documented inability to obtain a repeat sample (eg, due to lack of testing supplies, limited testing capacity, results taking > 24 hours, etc), AND progressive disease suggestive of ongoing SARS-CoV-2 infection 3 Evidence of respiratory failure attributable to COVID-19 pneumonia (documented radiographically) before enrollment 4 Nasogastric tube or other types of oral or percutaneous gastric feeding tube; placement must be radiographically confirmed and expected to remain in place, as judged by the investigator, for a minimum of 3 days after study enrolment.

      5 Has received treatment with PPIs (eg, omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole) for a minimum of 24 hours immediately prior to enrollment; any PPI will be permitted, provided it meets the minimum equivalent daily dose of 20 mg rabeprazole.

      Exclusion Criteria:

      1. Any serious and uncorrectable medical condition or abnormality of clinical laboratory tests that, in the Investigator's judgment, precludes the participant's safe participation in and completion of the study.
      2. In the opinion of the Investigator, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments.
      3. Current refractory nausea and vomiting, malabsorption syndrome, disease significantly affecting gastrointestinal function, resection of the stomach, extensive small bowel resection that is likely to affect absorption, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass.
      4. Received BTK inhibitor within 7 days before enrollment.
      5. Requires or is receiving anticoagulation with warfarin or equivalent vitamin K antagonists (eg, phenprocoumon) within 7 days prior to enrollment. Other anticoagulants are permitted.
      6. Participants on dual antiplatelet and therapeutic anticoagulant therapy (eg, aspirin and therapeutic doses of low molecular weight heparin are not allowed; however, aspirin and prophylactic/ low doses of low-molecular-weight heprin are allowed).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04497948


Locations
Layout table for location information
United States, Maryland
Research Site
Baltimore, Maryland, United States, 21287
United States, Minnesota
Research Site
Rochester, Minnesota, United States, 55905
United States, North Carolina
Research Site
Chapel Hill, North Carolina, United States, 27599-7081
United States, Pennsylvania
Research Site
Philadelphia, Pennsylvania, United States, 19140
Brazil
Research Site
Porto Alegre, Brazil, 90035-003
Research Site
Ribeirão Preto, Brazil, 14051-140
Research Site
Sao Paulo, Brazil, 01321-001
Research Site
Sao Paulo, Brazil, 01323-903
Sponsors and Collaborators
Acerta Pharma BV
AstraZeneca
Layout table for additonal information
Responsible Party: Acerta Pharma BV
ClinicalTrials.gov Identifier: NCT04497948    
Other Study ID Numbers: D822FC00005
First Posted: August 4, 2020    Key Record Dates
Last Update Posted: December 2, 2020
Last Verified: November 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Time Frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access Criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
URL: https://astrazenecagroup-dt.pharmacm.com/DT/Home

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Acerta Pharma BV:
2019 novel coronavirus disease
Acalabrutinib
Btk inhibitor